Clinical Scorecard: Collagenase Effective for Recurrent Dupuytren
At a Glance
| Category | Detail |
|---|---|
| Condition | Recurrent Dupuytren contracture |
| Key Mechanisms | Injection therapy with collagenase clostridium histolyticum (CCH) |
| Target Population | Patients with recurrence of Dupuytren contracture after prior surgery |
| Care Setting | Multicenter clinical settings in the US |
Key Highlights
- CCH injections provide a nonsurgical treatment option for recurrent Dupuytren contracture.
- Clinical success achieved in 65% of treated joints at first evaluation.
- Average improvement in joint extension of 38° within 12 months post-treatment.
- Safety profile consistent with previous reports; skin tears most common complication.
- Surgical retreatment carries higher complication risks compared to CCH therapy.
Guideline-Based Recommendations
Diagnosis
- Define recurrence as a functionally considerable increase in flexion contracture of at least 20°.
Management
- Consider collagenase clostridium histolyticum injections for patients with recurrent Dupuytren contracture.
Monitoring & Follow-up
- Evaluate joint extension improvements at 1 month and within 12 months post-treatment.
Risks
- Monitor for treatment-related adverse events, including skin tears and tendon ruptures.
Patient & Prescribing Data
101 patients with recurrent Dupuytren contracture, mean age 64 years.
CCH treatment is effective and well tolerated, with outcomes comparable to primary treatment.
Clinical Best Practices
- Assess the severity of contracture and joint involvement before treatment.
- Educate patients on the risks of repeat surgery versus CCH therapy.
- Monitor for adverse events post-injection and provide appropriate follow-up care.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
